Interferon

Clinical Review of Pegylated Interferons Suggests Formulation and Mechanism of Action May Improve Outcomes for MPN Patients

Retrieved on: 
Wednesday, February 21, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Myeloproliferative neoplasm, PV, University of Alabama, PMF, News, Treatment, Polycythemia, Manuscript, Interferon, Safety, University, Contraindication, Primary myelofibrosis, Associate, Patient, MPN, Pharmaceutical industry

The manuscript, "Interferons in the Treatment of Myeloproliferative Neoplasms” was co-authored by 12 renowned myeloproliferative neoplasm (MPN) specialists and published in Therapeutic Advances in Hematology .

Key Points: 
  • The manuscript, "Interferons in the Treatment of Myeloproliferative Neoplasms” was co-authored by 12 renowned myeloproliferative neoplasm (MPN) specialists and published in Therapeutic Advances in Hematology .
  • Writing and editorial support were funded by PharmaEssentia, however authors retained full editorial control and provided final approval on all content.
  • “Interferons are immune modulators that have been used to treat MPNs for more than 35 years.
  • “This review will continue to help the greater medical community better understand the potential of interferons, as well as potential dosing regimens and combination therapies for patients,” said Albert Qin, M.D., Ph.D., Chief Medical Officer, PharmaEssentia.

MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer

Retrieved on: 
Wednesday, February 7, 2024
Research, FDA, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, UTSW, Telomerase, SCLC, Interferon, Nature Communications, Clinical trial, Carcinoma, Diagnosis, Lung cancer, Orphan, Cancer, University

MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the publication of extensive work describing preclinical studies for lead candidate THIO in small cell lung cancer (SCLC) in the peer-reviewed scientific journal Nature Communications .

Key Points: 
  • MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the publication of extensive work describing preclinical studies for lead candidate THIO in small cell lung cancer (SCLC) in the peer-reviewed scientific journal Nature Communications .
  • “This publication highlights a rather unique dual mechanism of action for THIO as a first-in-clinic telomere-targeted anticancer agent for potential treatment of SCLC,” said Sergei M. Gryaznov, PhD., MAIA’s Chief Scientific Officer.
  • Key findings in the published paper include:
    “With few, if any, effective treatments for small cell lung cancer, there is a widespread need for innovative therapeutic strategies.
  • The positive outcomes reported in our publication show THIO’s potential as a new therapeutic approach,” said Vlad Vitoc, M.D., MAIA’s Chairman and Chief Executive Officer.

MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe

Retrieved on: 
Wednesday, December 6, 2023
Interferon, Risk, Tokyo Stock Exchange, Disability, Multiple sclerosis, Patent, PPMS, SPMS, MD, Code, MPH, Patient, Pharmaceutical industry

Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than October 2039.

Key Points: 
  • Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than October 2039.
  • The allowed claims cover MN-166 (ibudilast) and interferon-beta administered in separate dosage forms, administered in the same dosage form, administered simultaneously, or administered consecutively.
  • The allowed claims specifically cover the treatment of both primary progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis (SPMS).
  • The U.S. Patent and Trademark Office previously granted a similar patent covering this combination for the treatment of progressive MS."

Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®

Retrieved on: 
Friday, November 10, 2023
Hepatology, VBR, Interferon, Viral, SAN, Hepatitis B virus, AASLD, Liver, Biotechnology, Patient, HBV, ISG, Assembly, HCV, Doctor of Philosophy, Poster, Pharmaceutical industry, Vaccine, Boston

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced new data from its virology portfolio featured in two presentations at the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting®, taking place November 10-14, 2023, in Boston.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced new data from its virology portfolio featured in two presentations at the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting®, taking place November 10-14, 2023, in Boston.
  • “Additionally, the Phase 2 data reported for vebicorvir in combination with Nrtl and Arbutus Biopharma’s AB-729 provide further insights that may inform future studies for the HBV and liver disease scientific community."
  • In addition, oral administration to preclinical species resulted in ISG induction in the liver and peripheral blood mononuclear cells (PBMCs).
  • Assembly Bio intends to make the presentations available on the “Events & Presentations” page in the “Investors” section of its website at www.assemblybio.com.

Global Recombinant Protein Therapeutics CDMO Market Analysis Report 2023-2030: Increasing Rate of Clinical Research to Boost Demand for Recombinant Protein Therapeutics - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 7, 2023
Biotechnology, Pharmaceutical, Genetics, Health, Conditional sentence, Prevalence, CDMO, Investment, Sanofi, Endocrine gland, Vaccine, USD, GSK, COVID-19, Therapy, Biomedical Research, Antibody, Growth, Fine chemical, Interferon

The global recombinant protein therapeutics CDMO market size is expected to reach USD 51.95 billion by 2030, expected to grow at a CAGR of 13.9% from 2023 to 2030.

Key Points: 
  • The global recombinant protein therapeutics CDMO market size is expected to reach USD 51.95 billion by 2030, expected to grow at a CAGR of 13.9% from 2023 to 2030.
  • Increasing prevalence of chronic diseases, advancements in biotechnology, the rising prominence of personalized medicine, and increasing biomedical research and development investments are the key factors driving the growth of the market.
  • The growing demand for recombinant protein therapeutics has increased investment in biopharmaceutical manufacturing infrastructure and facilities.
  • The expanded manufacturing capacity enables greater production of recombinant protein therapeutics, thereby augmenting the market growth.

Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023

Retrieved on: 
Monday, November 13, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Hepatology, INSERM, Immunity, Interferon, Immune system, ALT, HDV, HBsAg, AASLD, Clinical trial, Viral hepatitis, EOT, Patient, Small RNA, Abstract, Week, Monoclonal antibody, Liver, Auckland City Hospital, CHB, University, Peginterferon-alfa, CHD, APHP, Hepatitis, Vir, RNA, Vaccine, Pharmaceutical industry, Communications satellite, Treatment, Medicine

To date, no participants receiving the combination therapy or VIR-3434 monotherapy have experienced ALT elevations relative to their baseline.

Key Points: 
  • To date, no participants receiving the combination therapy or VIR-3434 monotherapy have experienced ALT elevations relative to their baseline.
  • “Chronic hepatitis delta is the most aggressive form of viral hepatitis.
  • Vir will host an investor conference call to discuss the Phase 2 CHD & CHB AASLD data at 1:45 p.m. Pacific Time / 4:45 p.m. Eastern Time on November 13th.
  • A live webcast will be available on https://investors.vir.bio and will be archived on www.vir.bio for 30 days.

Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023

Retrieved on: 
Friday, November 10, 2023
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Hepatology, INSERM, Interferon, AASLD, Viral hepatitis, Patient, EOT, Abstract, Monoclonal antibody, Liver, Auckland City Hospital, CHB, University, CHD, APHP, Hepatitis, Vaccine, Treatment, Medicine, Boston

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that VIR-3434 and VIR-2218 could have for chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) patients at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in Boston, MA, from November 10-14, 2023.

Key Points: 
  • Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that VIR-3434 and VIR-2218 could have for chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) patients at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in Boston, MA, from November 10-14, 2023.
  • These include one late-breaking poster presentation and one late-breaking oral presentation.
  • Title: VIR-2218 and VIR-3434 With or Without Pegylated Interferon Alfa-2A for the Treatment of Chronic HBV Infection: End of Treatment (EOT) Results After 24 Weeks of Therapy (March Study Part B) (Abstract #48500)
    Presenter: Edward Gane, M.D., Professor of Medicine at the University of Auckland, New Zealand, and Chief Hepatologist, Transplant Physician and Deputy Director of the New Zealand Liver Transplant Unit at Auckland City Hospital
    Title: The Monoclonal Antibody VIR-3434 And siRNA VIR-2218 for the Treatment of Chronic Hepatitis D Virus: Preliminary Results from the Phase 2 SOLSTICE Trial (Abstract #5004)
    Presenter: Tarik Asselah, M.D., Ph.D., Professor of Hepatology at the Hôpital Beaujon, APHP, Clichy, France, and at the University of Paris, and Head of Viral Hepatitis at INSERM UMR1149, France
    Vir will host an investor conference call to discuss the Phase 2 CHD & CHB AASLD data at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on November 13th.
  • A live webcast will be available on https://investors.vir.bio and will be archived on www.vir.bio for 30 days.

CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 7, 2023
EGFR, Neoplasm, Bristol Myers Squibb, Research, Trial of the century, NSCLC, CD71, CD3, PDT, EDT, MSS, Regeneron Pharmaceuticals, Colorectal cancer, Workforce, Conference, PD-1, Inflammation, Ipilimumab, Interferon, BMS, Epithelial cell adhesion molecule, SITC, Immunotherapy, Preclinical development, ADC, CRC, Amgen, Webcast, Annual general meeting, Tumor microenvironment, Therapeutic index, Lung cancer, Society, Society for Immunotherapy of Cancer, Therapy, Patient, Investment, Toxicity, SAN, TCB, Pharmaceutical industry, Vaccine, IND, Astellas Pharma, Cancer

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today reported third quarter 2023 financial results and provided a business update.

Key Points: 
  • We have continued to diligently manage our financial resources and drive towards value-inflecting pipeline milestones,” said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX Therapeutics.
  • Preclinical profile of EpCAM-directed antibody drug conjugate CX-2051 presented at 2023 World ADC Conference – In October 2023, Dr. Marcia Belvin, chief scientific officer, CytomX Therapeutics, presented data characterizing the preclinical profile for CX-2051.
  • CX-2051 is tailored for treatment of EpCAM-expressing cancers by matching target expression and tumor sensitivity with a topoisomerase-1 inhibitor payload.
  • CytomX management will host a conference call and simultaneous webcast today at 5 p.m. EDT (2 p.m. PDT) to discuss the financial results and provide a business update.

A Breakthrough in Interferon-based Therapies for Multiple Sclerosis

Retrieved on: 
Tuesday, September 26, 2023
Partnership, Pediatrics, High-content screening, Biologic, Interferon, Mutation, Genomics, Multiple sclerosis, Doctor of Philosophy, Genetics, Biopharmaceutical, MD, Engineering, Drug discovery, Biosimilar, Insulin, UCLA, Health, Fine chemical

Using this comprehensive system, Heligenics analyzed ~5,000 genetic changes in the IFN gene and identified 70 promising biobetter sequence leads and an astonishing 1,300 biosimilar sequence leads.

Key Points: 
  • Using this comprehensive system, Heligenics analyzed ~5,000 genetic changes in the IFN gene and identified 70 promising biobetter sequence leads and an astonishing 1,300 biosimilar sequence leads.
  • The Heligenics GigaAssay technology enables engineering of improved Biologic drug versions, "biobetters," with significantly improved effectiveness.
  • These Interferon Beta variants hold immense promise in improving the first-line therapy for Multiple Sclerosis."
  • Heligenics is seeking opportunities to partner with pharmaceutical companies to: 1) take the Interferon Beta Biobetters to market, and 2) collaborate on multiple new biological drug projects.

With Orphan Drug Designation, Ainos' VELDONA Has Compelling Opportunity to Improve Quality of Life for HIV Patients

Retrieved on: 
Tuesday, September 19, 2023
Interferon, FDA, ODD, Patient, AIMD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Ainos, Pharmaceutical industry, Telescopic sight

Boston, Massachusetts--(Newsfile Corp. - September 19, 2023) - The U.S. Food and Drug Administration (FDA) has granted Ainos' (NASDAQ: AIMD) VELDONA Orphan Drug Designation (ODD) for the treatment of oral warts in HIV-seropositive patients.

Key Points: 
  • Boston, Massachusetts--(Newsfile Corp. - September 19, 2023) - The U.S. Food and Drug Administration (FDA) has granted Ainos' (NASDAQ: AIMD) VELDONA Orphan Drug Designation (ODD) for the treatment of oral warts in HIV-seropositive patients.
  • An estimated 24,000 HIV-seropositive Americans suffer from chronic oral warts.
  • Ainos plans to seek a pre-IND meeting with the U.S. FDA, with plans to advance VELDONA into a Phase 3 study for oral warts.
  • We estimate in excess of a $1 Billion global market opportunity for the company.